Plamotamab帕拉莫妥单抗帕拉莫妥单抗,2138442

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Plamotamab

CAS No. : 2138442-31-4

MCE 国际站：Plamotamab

产品活性：Plamotamab (XmAb-13676) 是一种人双特异性抗体 (bsAb)，可结合 CD3 和 CD20。 Plamotamab 招募细胞毒性 T 细胞来杀死表达 CD20⁺ 肿瘤细胞。Plamotamab 在体内诱导了轻微的血液学反应 (MR)，并导致体内的肿瘤消退。

研究领域：Immunology/Inflammation

作用靶点：CD20  |  CD3

In Vitro: Plamotamab induces the killing of endogenous B cells and activation of endogenous CD8⁺ T cells within human PBMCs in vitro, with an EC₅₀ value of 0.113 nM.
Plamotamab induces T cell-mediated killing in Raji tumor cells in vitro, with an EC₅₀ value of 0.144 nM.
Plamotamab binds to CD3δ/ε, CD3⁺ T cells, CD4⁺ T cells, CD8⁺ T cells, B cells, Raji cells, with EC₅₀s of 2.1 nM, 11.78 nM, 10.12 nM, 200.3 nM, and 134.8 nM, respectively.

In Vivo: Plamotamab (0.17 mg/kg; i.p.) causes tumor growth suppression in human PBMC-engrafted mouse model containing Raji xenograft.
Plamotamab (0.3 mg/kg; i.p.) leads to cytokine release in cynomolgus monkeys, indicating a safety to be improved.

相关产品：Rituximab  |  Obinutuzumab  |  Teclistamab  |  Mosunetuzumab  |  Glofitamab  |  Talquetamab  |  Ofatumumab  |  Muromonab  |  Cibisatamab  |  Solitomab  |  Teplizumab  |  Odronextamab  |  Pavurutamab  |  Cevostamab  |  Epcoritamab  |  Voxalatamab  |  Catumaxomab  |  Foralumab  |  Gresonitamab  |  Nivatrotamab  |  Otelixizumab  |  Pasotuxizumab  |  Anti-Mouse CD3 Antibody (17A2)  |  Blontuvetmab  |  Ocrelizumab  |  Pacanalotamab  |  Tepoditamab  |  Ublituximab  |  Dafsolimab

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds